The Role of Surrogate Markers in the Clinical Development of Antiretroviral Therapy: A Model for Early Evaluation of Targeted Cancer Drugs

Cancer Investigation

Volumn 22, Issue 1, 2004, Pages 149-160

  Petrella, Marco ^a   Montaner, Julio ^c   Batist, Gerald ^b   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; CD4 cell counts; HIV

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARMUSTINE; CD4 ANTIGEN; CETUXIMAB; CYTOSTATIC AGENT; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IMATINIB; SEMAXANIB; SU 5415; TEMOZOLOMIDE;

CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DISEASE MARKER; DRUG SCREENING; GENE FUNCTION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VIRUS LOAD;

EID: 1942441393     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120027590     Document Type: Review

References (135)

1. Carpenter, C.C.; Cooper, D.A.; Fischl, M.A.; Gatell, J.M.; Gazzard, B.G. ; Hammer, S.M.; Hirsch, M.S.; Jacobsen, D.M.; Katzenstein, D.A.; Montaner, J.S. ; Richman, D.D.; Saag, M.S.; Schechter, M.; Schooley, R.T.; Thompson, M.A.; Vella, S.; Yeni, P.G.; Volberding, P.A. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283 (3), 381-390.
2. Richman, D.D. HIV chemotherapy. Nature 2001, 410 (6831), 995-1001.
3. Fan, W.; Johnson, K.R.; Miller, M.C., III. In vitro evaluation of combination chemotherapy against human tumor cells (Review). Oncol. Rep. 1998, 5 (5), 1035-1042.
4. Murray, N. The importance of drug diversity in the treatment of small cell lung cancer. Semin. Oncol. 2001, 28 (2 Suppl 4), 38-42.
5. Bunn, P.A., Jr. Triplet combination chemotherapy and targeted therapy regimens. Oncology (Huntingt) 2001, 15 (3 Suppl 6), 26-32.
6. Esteva, F.J.; Valero, V.; Pusztai, L.; Boehnke-Michaud, L.; Buzdar, A.U. ; Hortobagyi, G.N. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001, 6 (2), 133-146.
7. Palella, F.J.; Delaney, K.M.; Moorman, A.C.; et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 1998, 338, 853-860.
8. Hogg, R.S.; Heath, R.V.; Yip, B.; et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998, 279, 450-454.
9. Mocroft, A.; Katlama, C.; Johnson, A.M.; et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000, 356, 291-296.
10. Kartsonis, N.A.; D'Aquila, R.T. Clinical monitoring of HIV-1 infection in the ERA of antiretroviral resistance testing. Infect. Dis. Clin. North Am. 2000, 14 (4), 879-899.
11. Fischl, M.A. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection. AIDS 1999, 13 (Suppl 1), S49-S59.
12. Cole, B.F.; Gelber, R.D.; Gelber, S.; Coates, A.S.; Goldhirsch, A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001, 358 (9278), 277-286.
13. Haller, D.G. Update on chemotherapy for advanced colorectal cancer. Oncology (Huntingt) 2001, 15 (3 Suppl 5), 11-15.
14. Shah, M.A.; Schwartz, G.K. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 2001, 7 (8), 2168-2181.
15. Szabo, D.; Keyzer, H.; Kaiser, H.E.; Molnar. Reversal of multidrug resistance of tumor cells. J. Anticancer Res. 2000, 20 (6B), 4261-4274.
16. Galmarini, C.M.; Mackey, J.R.; Dumontet, C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001, 15 (6), 875-890.
17. Carr, A.; Cooper, D.A. Adverse effects of antiretroviral therapy. Lancet 2000, 356 (9239), 1423-1430.
18. Jain, R.G.; Furfine, E.S.; Pedneault, L.; White, A.J.; Lenhard, J.M. Metabolic complications associated with antiretroviral therapy. Antivir. Res. 2001, 51 (3), 151-177.
19. Brinkman, K.; Smeitink, J.A.; Romijn, J.A.; Reiss, P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354 (9184), 1112-1115.
20. Burger, D.M.; Hoetelmans, R.M.; Koopmans, P.P.; Meenhorst, P.L.; Mulder, J.W.; Hekster, Y.A.; Beijnen, J.H. Clinically relevant drug interactions with antiretroviral agents. Antivir. Ther. 1997, 2 (3), 149-165.
21. Furlan, V.; Taburet, A.M. Drug interactions with antiretroviral agents. Therapie 2001, 56 (3), 267-271.
22. Smorenburg, C.H.; Sparreboom, A.; Bontenbal, M.; Verweij, J. Combination chemotherapy of the taxanes and antimetabolites. Its use and limitations. Eur. J. Cancer 2001, 37 (18), 2310-2323.
23. Peto, T. Surrogate markers in HIV disease. J. Antimicrob. Chemother. 1996, 37 (Suppl B), 161-170.
24. Montaner, J.S.; DeMasi, R.; Hill, A.M. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998, 12 (5), F23-F28.
25. Marschner, I.C.; Collier, A.C.; Coombs, R.W.; D'Aquila, R.T.; DeGruttola, V.; Fischl, M.A.; Hammer, S.M.; Hughes, M.D.; Johnson, V.A.; Katzenstein, D.A. ; Richman, D.D.; Smeaton, L.M.; Spector, S.A.; Saag, M.S. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 1998, 177 (1), 40-47.
26. Zackin, R.; Marschner, I.; Andersen, J.; Cowles, M.K.; De Gruttola, V.; Hammer, S.; Fischl, M.; Cotton, D. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping. J. Infect. Dis. 1998, 177 (3), 761-765.
27. Demeter, L.M.; Hughes, M.D.; Coombs, R.W.; Jackson, J.B.; Grimes, J.M.; Bosch, R.J.; Fiscus, S.A.; Spector, S.A.; Squires, K.E.; Fischl, M.A.; Hammer, S.M. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS clinical trials group protocol 320. Ann. Intern. Med. 2001, 135 (11), 954-964.
28. Hogg, R.S.; Yip, B.; Chan, K.J.; Wood, E.; Craib, K.J.; O'Shaughnessy, M.V.; Montaner, J.S. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001, 286 (20), 2568-2577.
29. Delta Coordinating Committee; Delta Virology Committee. HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study. AIDS 1999, 13 (1), 57-65.
30. Raboud, J.M.; Rae, S.; Montaner, J.S. Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups. J. Acquir. Immune Defic. Syndr. 2000, 24 (5), 433-439.
31. Lange, J.M. Changing therapy in HIV. AIDS 1996, 10 (Suppl 1), S27-S30.
32. Polis, M.A.; Sidorov, I.A.; Yoder, C.; Jankelevich, S.; Metcalf, J.; Mueller, B.U.; Dimitrov, M.A.; Pizzo, P.; Yarchoan, R.; Dimitrov, D.S. Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy. Lancet 2001, 358 (9295), 1760-1765.
33. Mylonakis, E.; Paliou, M.; Rich, J.D. Plasma viral load testing in the management of HIV infection. Am. Fam. Phys. 2001, 63 (3), pp. 483-490, 495-496.
34. Bain, V.G. Effect of HCV viral dynamics on treatment design: lessons learned from HIV. Am. J. Gastroenterol. 2001, 96 (10), 2818-2828.
35. Hanna, G.J.; D'Aquila, R.T. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin. Infect. Dis. 2001, 32 (5), 774-782.
36. Schmidt, B.; Korn, K.; Walter, H. Technologies for measuring HIV-1 drug resistance. HIV Clin. Trials 2002, 3 (3), 227-236.
37. Youree, B.E.; D'Aquila, R.T. Antiretroviral resistance testing for clinical management. AIDS Rev. 2002, 4 (1), 3-12.
38. Demeter, L.; Haubrich, R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J. Acquir. Immune Defic. Syndr. 2001, 26 (Suppl 1), S3-S9.
39. Lerma, J.G.; Heneine, W. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J. Clin. Virol. 2001, 21 (3), 197-212.
40. Dunne, A.L.; Mitchell, F.M.; Coberly, S.K.; Hellmann, N.S.; Hoy, J.; Mijch, A.; Petropoulos, C.J.; Mills, J.; Crowe, S.M. Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. AIDS 2001, 15 (12), 1471-1475.
41. Durant, J.; Clevenbergh, P.; Halfon, P.; Delgiudice, P.; Porsin, S.; Simonet, P.; Montagne, N.; Boucher, C.A.; Schapiro, J.M.; Dellamonica, P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353 (9171), 2195-2199.
42. Baxter, J.D.; Mayers, D.L.; Wentworth, D.N.; Neaton, J.D.; Hoover, M.L.; Winters, M.A.; Mannheimer, S.B.; Thompson, M.A.; Abrams, D.I.; Brizz, B.J.; Ioannidis, J.P.; Merigan, T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 2000, 14 (9), F83-F93.
43. Call, S.A.; Saag, M.S.; Westfall, A.O.; Raper, J.L.; Pham, S.V.; Tolson, J.M.; Hellmann, N.S.; Cloud, G.A.; Johnson, V.A. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 2001, 183 (3), 401-408.
44. Meynard, J.L.; Vray, M.; Morand-Joubert, L.; Race, E.; Descamps, D.; Peytavin, G.; Matheron, S.; Lamotte, C.; Guiramand, S.; Costagliola, D.; Brun-Vezinet, F.; Clavel, F.; Girard, P.M.; The Narval Trial Group Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002, 16 (5), 727-736.
45. Torre, D.; Tambini, R. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin. Trials 2002, 3 (1), 1-8.
46. Cohen, C.J.; Hunt, S.; Sension, M.; Farthing, C.; Conant, M.; Jacobson, S.; Nadler, J.; Verbiest, W.; Hertogs, K.; Ames, M.; Rinehart, A.R.; Graham, N.M. VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002, 16 (4), 579-588.
47. Chaix, C.; Grenier-Sennelier, C.; Clevenbergh, P.; Durant, J.; Schapiro, J.M.; Dellamonica, P.; Durand-Zaleski, I. Economic evaluation of drug resistance genotyping for the adaptation of treatment in HIV-infected patients in the VIRADAPT study. J. Acquir. Immune Defic. Syndr. 2000, 24 (3), 227-231.
48. Weinstein, M.C.; Goldie, S.J.; Losina, E.; Cohen, C.J.; Baxter, J.D.; Zhang, H.; Kimmel, A.D.; Freedberg, K.A. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann. Intern. Med. 2001, 134 (6), 440-450.
49. Hirsch, M.S.; Brun-Vezinet, F.; D'Aquila, R.T.; Hammer, S.M.; Johnson, V.A.; Kuritzkes, D.R.; Loveday, C.; Mellors, J.W.; Clotet, B.; Conway, B.; Demeter, L.M.; Vella, S.; Jacobsen, D.M.; Richman, D.D. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283 (18), 2417-2426.
50. Harrigan, P.R.; Cote, H.C. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin. Infect. Dis. 2000, 30 (Suppl 2), S117-S122.
51. Palumbo, P.; Holland, B.; Dobbs, T.; Pau, C.P.; Luo, C.C.; Abrams, E.J.; Nesheim, S.; Vink, P.; Respess, R.; Bulterys, M. Perinatal AIDS collaborative transmission study. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J. Infect. Dis. 2001, 184 (9), 1120-1126.
52. Kerr, D.J. Phase I clinical trials: adapting methodology to face new challenges. Ann. Oncol. 1994, 5 (Suppl 4), 67-70.
53. Tolcher, A.W. Novel compounds in the therapy of breast cancer: opportunities for integration with docetaxel. Oncologist 2001, 6 (Suppl 3), 40-44.
54. Eskens, F.A.; Verweij, J. Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. Crit. Rev. Oncol. Hematol. 2000, 34 (2), 83-88.
55. Saijo, N.; Tamura, T.; Nishio, K. Problems in the development of target-based drugs. Cancer Chemother. Pharmacol. 2000, 46 (Suppl), S43-S45.
56. Rowinsky, E.K. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs 2000, 60 (Suppl 1), 1-14.
57. Perera, F.P.; Weinstein, I.B. Molecular epidemiology: recent advances and future directions. Carcinogenesis 2000, 21 (3), 517-524.
58. Kelloff, G.J.; Sigman, C.C.; Johnson, K.M.; Boone, C.W.; Greenwald, P.; Crowell, J.A.; Hawk, E.T.; Doody, L.A. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol. Biomarker. Prev. 2000, 9 (2), 127-137.
59. Syngal, S.; Clarke, G.; Bandipalliam, P. Potential roles of genetic biomarkers in colorectal cancer chemoprevention. J. Cell Biochem. Suppl. 2000, 34, 28-34.
60. De Gruttola, V.G.; Clax, P.; DeMets, D.L.; Downing, G.J.; Ellenberg, S.S.; Friedman, L.; Gail, M.H.; Prentice, R.; Wittes, J.; Zeger, S.L. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control Clin. Trials 2001, 22 (5), 485-502.
61. Bishop, H.M.; Blamey, R.W.; Elston, C.W.; Haybittle, J.L.; Nicholson, R.I.; Griffiths, K. Relationship of oestrogen-receptor status to survival in breast cancer. Lancet 1979, 2 (8137), 283-284.
62. McGuire, W.L. Prognostic factors in primary breast cancer. Cancer Surv. 1986, 5 (3), 527-536.
63. Ferno, M. Prognostic factors in breast cancer: a brief review. Anticancer Res 1998, 18 (3C), 2167-2171.
64. Chang, J.; Powles, T.J.; Allred, D.C.; Ashley, S.E.; Makris, A.; Gregory, R.K.; Osborne, C.K.; Dowsett, M. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin. Cancer Res. 2000, 6 (2), 616-621.
65. Bundred, N.J. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001, 27 (3), 137-142.
66. Scarpi, E.; De Paola, F.; Sarti, M.; Bajorko, P.; Granato, A.M.; Volpi, A.; Nanni, O.; Maltoni, R.; Amadori, D. Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 2001, 68 (2), 101-110.
67. Fukutomi, T.; Akashi-Tanaka, S. Prognostic and predictive factors in the adjuvant treatment of breast cancer. Breast Cancer 2002, 9 (2), 95-99.
68. Hawkins, R.A.; Tesdale, A.L.; Prescott, R.J.; Forster, T.; McIntyre, M.A.; Baker, P.; Jack, W.J.; Chetty, U.; Dixon, J.M.; Killen, M.E.; Hulme, M.J. ; Miller, W.R. Outcome after extended follow-up in a prospective study of operable breast cancer: key factors and a prognostic index. Br. J. Cancer 2002, 87 (1), 8-14.
69. Hamilton, A.; Piccart, M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann. Oncol. 2000, 11 (6), 647-663.
70. Ravdin, P. The use of HER2 testing in the management of breast cancer. Semin. Oncol. 2000, 27 (5 Suppl 9), 33-42.
71. Yamauchi, H.; Stearns, V.; Hayes, D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 2001, 19 (8), 2334-2356.
72. Piccart, M.J.; Di Leo, A.; Hamilton, A. HER2. A 'predictive factor' ready to use in the daily management of breast cancer patients? Eur. J. Cancer 2000, 36 (14), 1755-1761.
73. Sahin, A.A. Biologic and clinical significance of HER-2/neu (cerbB-2) in breast cancer. Adv. Anat. Pathol. 2000, 7 (3), 158-166.
74. Hayes, D.F.; Yamauchi, H.; Broadwater, G.; Cirrincione, C.T.; Rodrigue, S.P.; Berry, D.A.; Younger, J.; Panasci, L.L.; Millard, F.; Duggan, D.B.; Norton, L.; Henderson, I.C. Cancer and leukemia group B. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: cancer and leukemia group B study 8662. Clin. Cancer Res. 2001, 7 (9), 2703-2711.
75. Hait, W.N. The prognostic and predictive values of ECD-HER-2. Clin. Cancer Res. 2001, 7 (9), 2601-2604.
76. Yamauchi, H.; Stearns, V.; Hayes, D.F. The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 2001, 8 (3), 171-183.
77. Mauro, M.J.; Druker, B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 2001, 6 (3), 233-238.
78. Druker, B.J. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002, 1 (1), 31-36.
79. Demetri, G.D. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin. Oncol. 2001, 28 (5 Suppl 17), 19-26.
80. Allander, S.V.; Nupponen, N.N.; Ringner, M.; Hostetter, G.; Maher, G.W.; Goldberger, N.; Chen, Y.; Carpten, J.; Elkahloun, A.G.; Meltzer, P.S. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res. 2001, 61 (24), 8624-8628.
81. Hoover, R.R.; Mahon, F.X.; Melo, J.V.; Daley, G.Q. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002, 100 (3), 1068-1071.
82. Scappini, B.; Onida, F.; Kantarjian, H.M.; Dong, L.; Verstovsek, S.; Keating, M.J.; Beran, M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer 2002, 94 (10), 2653-2662.
83. Roche-Lestienne, C.; Soenen-Cornu, V.; Grardel-Duflos, N.; Lai, J.L.; Philippe, N.; Facon, T.; Fenaux, P.; Preudhomme, C. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100 (3), 1014-1018.
84. Roumiantsev, S.; Shah, N.P.; Gorre, M.E.; Nicoll, J.; Brasher, B.B.; Sawyers, C.L.; Van Etten, R.A. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc. Natl. Acad Sci. U. S. A. 2002, 99 (16), 10700-10705.
85. Bidart, J.M.; Thuillier, F.; Augereau, C.; Chalas, J.; Daver, A.; Jacob, N.; Labrousse, F.; Voitot, H. Kinetics of serum tumor marker concentrations and usefulness in clinical monitoring. Clin. Chem. 1999, 45 (10), 1695-1707.
86. Duffy, M.J. Clinical uses of tumor markers: a critical review. Crit. Rev. Clin. Lab. Sci. 2001, 38 (3), 225-262.
87. Canil, C.M.; Tannock, I.F. Doctor's dilemma: incorporating tumor markers into clinical decision-making. Semin. Oncol. 2002, 29 (3), 286-293.
88. Kohn, J.; Orr, A.H.; McElwain, T.J.; Bentall, M.; Peckham, M.J. Serum-alpha 1-fetoprotein in patients with testicular tumours. Lancet 1976, 1 (7982), 433-436.
89. Gregory, J.J., Jr.; Finlay, J.L. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs 1999, 57 (4), 463-467.
90. Inanc, S.E.; Meral, R.; Darendeliler, E.; Yasasever, V.; Onat, H. Prognostic significance of marker half-life during chemotherapy in non-seminomatous germ cell testicular tumors. Acta Oncol. 1999, 38 (4), 505-509.
91. Mazumdar, M.; Bajorin, D.F.; Bacik, J.; Higgins, G.; Motzer, R.J.; Bosl, G.J. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J. Clin. Oncol. 2001, 19 (9), 2534-2541.
92. Schneider, D.T.; Calaminus, G.; Gobel, U. Diagnostic value of alpha 1-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. Pediatr. Hematol. Oncol. 2001, 18 (1), 11-26.
93. Trigo, J.M.; Tabernero, J.M.; Paz-Ares, L.; García-Llano, J.L.; Mora, J.; Lianes, P.; Esteban, E.; Salazar, R.; López-López, J.J. ; Cortés-Funes, H. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000, 88 (1), 162-168.
94. Kardamakis, D. Tumour serum markers: clinical and economical aspects. Anticancer Res. 1996, 16 (4B), 2285-2288.
95. Small, E.J.; Roach, M., III. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol 2002, Jun, 29 (3), 264-273.
96. Chu, T.M. Prostate-specific antigen and early detection of prostate cancer. Tumour Biol. 1997, 18 (2), 123-134.
97. Ornstein, D.K.; Pruthi, R.S. Prostate-specific antigen. Expert. Opin. Pharmacother. 2000, 1 (7), 1399-1411.
98. Gao, X.; Porter, A.T.; Grignon, D.J.; Pontes, J.E.; Honn, K.V. Diagnostic and prognostic markers for human prostate cancer. Prostate 1997, 31 (4), 264-281.
99. Wilt, T.J. Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer. Semin. Urol. Oncol. 2002, 20 (1), 10-17.
100. Cookson, M.M. Prostate cancer: screening and early detection. Cancer Control 2001, 8 (2), 133-140.
101. Perrotti, M. Understanding PSA and prostate cancer risk assessment. N. J. Med. 2001, 98 (6), 35-38.
102. Duffy, M.J. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin. Chem. 2001, 47 (4), 624-630.
103. Macdonald, J.S. Carcinoembryonic antigen screening: pros and cons. Semin. Oncol. 1999, 26 (5), 556-560.
104. Wichmann, M.W.; Lau-Werner, U.; Muller, C.; Hornung, H.M.; Stieber, P.; Schildberg, F.W.; The Colorectal Cancer Study Group Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Res. 2000, 20 (6D), 4953-4955.
105. Brent, T.P.; Houghton, P.J.; Houghton, J.A. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc. Natl. Acad Sci. U. S. A. 1985, 82 (9), 2985-2989.
106. Hobin, D.A.; Fairbaim, L.J. Genetic chemoprotection with mutant O6-alkylguanine-DNA-alkyltransferases. Curr. Gene Ther. 2002, 2 (1), 1-8.
107. Pegg, A.E. Repair of O (6)-alkylguanine by alkyltransferases. Mutat. Res. 2000, 462 (2-3), 83-100.
108. Gerson, S.L. Clinical relevance of MGMT in the treatment of cancer. J. Clin. Oncol. 2002, 20 (9), 2388-2399.
109. Koc, O.N.; Phillips, W.P., Jr.; Lee, K.; Liu, L.; Zaidi, N.H.; Allay, J.A.; Gerson, S.L. Role of DNA repair in resistance to drugs that alkylate O6 of guanine. Cancer Treat Res. 1996, 87, 123-146.
110. Esteller, M.; Garcia-Foncillas, J.; Andion, E.; Goodman, S.N.; Hidalgo, O.F.; Vanaclocha, V.; Baylin, S.B.; Herman, J.G. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 2000, 343 (19), 1350-1354.
111. Clemons, M.J.; Bibby, M.C.; El Teraifi, H.; Forster, G.; Kelly, J.; Banerjee, S.; Cadman, B.; Ryder, W.D.; Howell, A.; Margison, G.P. Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. Br. J. Cancer 2002, 86 (11), 1797-1802.
112. Spiro, T.P.; Gerson, S.L.; Liu, L.; Majka, S.; Haaga, J.; Hoppel, C.L.; Ingalls, S.T.; Pluda, J.M.; Willson, J.K. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res. 1999, 59 (10), 2402-2410.
113. Schilsky, R.L.; Dolan, M.E.; Bertucci, D.; Ewesuedo, R.B.; Vogelzang, N.J.; Mani, S.; Wilson, L.R.; Ratain, M.J. Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer. Clin. Cancer Res. 2000, 6 (8), 3025-3031.
114. Friedman, H.S.; Pluda, J.; Quinn, J.A.; Ewesuedo, R.B.; Long, L.; Friedman, A.H.; Cokgor, I.; Colvin, O.M.; Haglund, M.M.; Ashley, D.M.; Rich, J.N.; Sampson, J.; Pegg, A.E.; Moschel, R.C.; McLendon, R.E.; Provenzale, J.M.; Stewart, E.S.; Tourt-Uhlig, S.; Garcia-Turner, A.M.; Herndon, J.E., II; Bigner, D.D.; Dolan, M.E. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 2000, 18 (20), 3522-3528.
115. Arteaga, C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002, 7 (Suppl 4), 31-39.
116. Albanell, J.; Rojo, F.; Averbuch, S.; Feyereislova, A.; Mascaro, J.M.; Herbst, R.; LoRusso, P.; Rischin, D.; Sauleda, S.; Gee, J.; Nicholson, R.I.; Baselga, J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 2002, 20 (1), 110-124.
117. Busam, K.J.; Capodieci, P.; Motzer, R.; Kiehn, T.; Phelan, D.; Halpern, A.C. Cutaneous side-effects in cancer patients treated with the anti-epidermal growth factor receptor antibody C225. Br. J. Dermatol. 2001, 144 (6), 1169-1176.
118. Ranson, M.; Hammond, L.A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P.I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H. ; Rowinsky, E.K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002, 20 (9), 2240-2250.
119. Albanell, J.; Rojo, F.; Baselga, J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin. Oncol. 2001, 28 (5 Suppl 16), 56-66.
120. Mendel, D.B.; Schreck, R.E.; West, D.C.; Li, G.; Strawn, L.M.; Tanciongco, S.S.; Vasile, S.; Shawver, L.K.; Cherrington, J.M. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res. 2000, 6 (12), 4848-4858.
121. Fong, T.A.; Shawver, L.K.; Sun, L.; Tang, C.; App, H.; Powell, T.J.; Kim, Y.H.; Schreck, R.; Wang, X.; Risau, W.; Ullrich, A.; Hirth, K.P.; McMahon, G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999, 59 (1), 99-106.
122. Mendel, D.B.; Laird, A.D.; Smolich, B.D.; Blake, R.A.; Liang, C.; Hannah, A.L.; Shaheen, R.M.; Ellis, L.M.; Weitman, S.; Shawver, L.K.; Cherrington, J.M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 2000, 15 (1), 29-41.
123. Carter, S.K. Clinical strategy for the development of angiogenesis inhibitors. Oncologist 2000, 5 (Suppl 1), 51-54.
124. Garber, K. Tyrosine kinase inhibitor research presses on despite halted clinical trial. J. Natl. Cancer Inst. 2000, 92 (12), 967-969.
125. Dowlati, A.; Haaga, J.; Remick, S.C.; Spiro, T.P.; Gerson, S.L.; Liu, L. ; Berger, S.J.; Berger, N.A.; Willson, J.K. Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. Clin. Cancer Res. 2001, 7 (10), 2971-2976.
126. Fung, E.T.; Wright, G.L., Jr.; Dalmasso, E.A. Proteomic strategies for biomarker identification: progress and challenges. Curr. Opin. Mol. Ther. 2000, 2 (6), 643-650.
127. Bichsel, V.E.; Liotta, L.A.; Petricoin, E.F., III. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 2001, 7 (1), 69-78.
128. Côté, H.; Brumme, Z.; Wynhoven, B.; Harris, M.; Craib, K.; Harrigan, P.; O'Shaughnessy, M.; Montaner, J. Mitochondrial DNA depletion in HIV+ patients with symptomatic nucleoside related mitochondrial toxicity. The 1st. IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina, 2001. [Abstract].
129. Côté, H.C.; Brumme, Z.L.; Craib, K.J.; Alexander, C.S.; Wynhoven, B.; Ting, L.; Wong, H.; Harris, M.; Harrigan, P.R.; O'Shaughnessy, M.V.; Montaner, J.S. Changes in peripheral blood mitochondrial DNA among HIV-infected patients experiencing nucleoside toxicity. N. Engl. J. Med. 2002, 346 (11), 811-820.
130. Li, J.; Zheng, L.M.; King, I.; Doyle, T.W.; Chen, S.H. Syntheses and antitumor activities of potent inhibitors of ribonucleotide reductase: 3-amino-4-methylpyridine-2-carboxaldehyde-thiosemicarba-zone (3-AMP), 3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) and its water-soluble prodrugs. Curr. Med. Chem. 2001, 8 (2), 121-133.
131. Seidman, A.D. The evolving role of gemcitabine in the management of breast cancer. Oncology 2001, 60 (3), 189-198.
132. Cunningham, D.; Coleman, R. New options for outpatient chemotherapy - the role of oral fluoropyrimidines. Cancer Treat Rev. 2001, 27 (4), 211-220.
133. Johnson, S.A.; Thomas, W. Therapeutic potential of purine analogue combinations in the treatment of lymphoid malignancies. Hematol. Oncol. 2000, 18 (4), 141-153.
134. Johnson, S.A. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies. Clin. Pharmacokinet. 2000, 39 (1), 5-26.
135. Johnson, S.A. Nucleoside analogues in the treatment of haematological malignancies. Expert. Opin. Pharmacother. 2001, 2 (6), 929-943.